The immunotherapy targeting the PD-1/PD-L1 pathway has shown significant and durable clinical responses for non-small-cell lung cancer (NSCLC) patients in addition to a more favorable toxicity profile and improved tolerability than chemotherapy [7]. Here, CD274 is linked to non-small cell lung carcinoma.